Analystreport

Royalty Pharma plc (NASDAQ: RPRX) was upgraded by analysts at TD Cowen to a "strong-buy" rating.

Royalty Pharma plc - Class A Ordinary Shares  (RPRX) 
US:NASDAQ Investor Relations: ir.reprosrx.com/investor-relations